Quick Answer
Vanda Pharmaceuticals Inc. reported Net Income Loss of -$220.47 million for the year ending 2025.
- Vanda Pharmaceuticals Inc. showed a decrease of -1,066.5% in Net Income Loss from 2024 to 2025.
- This data is from Vanda Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on February 12, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: -$12.36 million | Q2 2016: -$4.62 million | Q3 2016: -$430.0 thousand | Q4 2016: -$604.0 thousand | Q1 2017: -$7.65 million | Q2 2017: -$1.53 million | Q3 2017: -$4.55 million | Q4 2017: -$1.84 million | Q1 2018: $3.07 million | Q2 2018: $4.61 million | Q3 2018: $7.17 million | Q4 2018: $10.36 million | Q1 2019: -$612.0 thousand | Q2 2019: $11.53 million | Q3 2019: $100.42 million | Q4 2019: $4.22 million | Q1 2020: $486.0 thousand | Q2 2020: $8.71 million | Q3 2020: $5.95 million | Q4 2020: $8.19 million | Q1 2021: $8.65 million | Q2 2021: $9.65 million | Q3 2021: $7.77 million | Q1 2022: -$6.43 million | Q2 2022: $2.57 million | Q3 2022: $3.27 million | Q1 2023: $3.25 million | Q2 2023: $1.52 million | Q3 2023: $137.0 thousand | Q1 2024: -$4.15 million | Q2 2024: -$4.52 million | Q3 2024: -$5.32 million | Q1 2025: -$29.49 million | Q2 2025: -$27.21 million | Q3 2025: -$22.59 million.
- Over the full 17 years of available data (2009 to 2025), Vanda Pharmaceuticals Inc.'s Net Income Loss has declined by 514.8%.
- Historical annual values: Fiscal year 2025: -$220.47 million | Fiscal year 2024: -$18.90 million | Fiscal year 2023: $2.51 million | Fiscal year 2022: $6.28 million | Fiscal year 2021: $33.15 million | Fiscal year 2020: $23.34 million | Fiscal year 2019: $115.55 million | Fiscal year 2018: $25.21 million | Fiscal year 2017: -$15.57 million | Fiscal year 2016: -$18.01 million | Fiscal year 2015: -$39.87 million | Fiscal year 2014: $20.19 million | Fiscal year 2013: -$21.06 million | Fiscal year 2012: -$28.62 million | Fiscal year 2011: -$9.80 million | Fiscal year 2010: $7.19 million | Fiscal year 2009: -$35.86 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: